Oncimmune Holdings PLC Regulatory Approval in Israel for EarlyCDT®-Lung (0382Z)
May 15 2019 - 1:01AM
UK Regulatory
TIDMONC
RNS Number : 0382Z
Oncimmune Holdings PLC
15 May 2019
15 May 2019
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Regulatory Approval in Israel for EarlyCDT(R) -Lung
Oncimmune Holdings plc (AIM: ONC.L), a leader in the
development, manufacture and commercialisation of personalised
immunodiagnostics for the screening, detection and care of cancer,
today announces that its distributor for Israel, Best Medical
Opinion, has received regulatory approval for the sale of
EarlyCDT-Lung in Israel.
On an age standardised basis, Israel's lung cancer mortality
rate is 18.2 per 100,000 persons, making it one of the highest
rates in the Middle East region. Lung cancer is responsible for
more cancer-related deaths than any other cancer in Israel.(1)
Dr Adam M Hill, CEO of Oncimmune commented: "We welcome this
latest approval which paves the way for the near-term commencement
of commercial sales in the sophisticated healthcare market of
Israel."
-Ends-
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Mike Seabrook
+44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0)20 3709 5700
About Oncimmune
Beating cancer, one test at a time
Oncimmune is a leader in the development, manufacture and
commercialisation of cancer specific immunodiagnostics for the
screening, detection and care of cancer. Oncimmune also develops
precision medicine and patient stratification tools for leading
pharmaceutical multinationals in both immuno-oncology and
autoimmune disease. Oncimmune is working to change how cancer is
diagnosed and treated. Its patented technology detects evidence of
the body's natural response to cancer, enabling detection four
years or more before standard clinical diagnosis. Oncimmune's tests
facilitate clinical decision-making and are complementary to
diagnostic technologies, making them valuable additions to
established and new care pathways. Oncimmune partners with leading
developers and distributors to make our technology available
globally.
Oncimmune was founded in 2002 and launched its platform
technology in 2009, followed by its first commercial tests,
EarlyCDT-Lung and EarlyCDT-Liver. To date, over 155,000 tests have
been performed for patients worldwide and EarlyCDT-Lung is being
used in the largest-ever randomised trial for the early detection
of lung cancer using biomarkers, the National Health Service (NHS)
ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune,
headquartered at its laboratory facility in Nottingham, UK, has a
discovery research centre in Dortmund, Germany and a CLIA lab in
Kansas, US as well as offices in London, UK and Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
What is EarlyCDT-Lung?
A blood test using a panel of seven immunogenic proteins for the
testing of tumour-related antibodies specific to lung cancer.
For more information, visit www.oncimmune.com
(1) International Agency for Research on Cancer, World Health
Organization - 2018
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
REAEAFSLFFKNEAF
(END) Dow Jones Newswires
May 15, 2019 02:01 ET (06:01 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024